Clinical Trials

Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Is Odronextamab Effective if CAR-T Stops Working for DLBCL?

April 28, 2025

Learn how odronextamab may offer a new treatment option for DLBCL patients whose CD19 CAR T-cell therapy has stopped working.

Targeting ROR1 in Blood Cancers

April 16, 2025

Understanding how ROR1-targeted therapies work—and whether they apply to your specific blood cancer type—can help you make more informed treatment decisions.

Studying the Keto Diet's Impact on CAR T-Cells for Large B-Cell Lymphoma

February 05, 2025

Researchers explore if BHB from a keto diet can boost CAR T-cell therapy for LBCL patients. Clinical trials aim to assess its effectiveness.

Trial Updates on Zynlonta Combinations for DLBCL

January 08, 2025

Read insights from the LOTIS-7 trial which is evaluating Zynlonta combinations for diffuse large B-cell lymphoma.

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

November 19, 2024

Learn how golcadomide in combination with R-CHOP helped DLBCL patients in a phase 1 clinical trial.

New Clinical Trial with Armored CAR T-cells

October 01, 2024

Understanding CAR T-Cell Therapy and the Armored CAR T-Cell Trial

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

May 20, 2024

Columvi (Glofitamab) To Treat Relapsed Or Refractory DLBCL, new treatment option for DLBCL, Clinical Trial for DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

April 25, 2024

New study shows Brentuximab Vedotin combined therapy effective for relapsed DLBCL (lymphoma). Learn about ADCETRIS and its side effects.

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

October 16, 2023

Dr. Gunjan L. Shah and her team at MSK in NY are conducting a clinical trial to reverse T-cell exhaustion by pairing antioxidants alongside CAR T-cell therapy.

The FDA Approves Columvi For Relapsed/Refractory DLBCL

October 08, 2023

The Food and Drug Administration (FDA) approved Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)